Responses to CSR Appeals in Non-Prescription Drug Ads: Evidence from Brazil and the United States

2017 ◽  
pp. 133-155
Author(s):  
Isabell Koinig ◽  
Sandra Diehl ◽  
Barbara Mueller
Keyword(s):  
United States ◽  
Prescription Drug ◽  
The United States

Discrepancies in the Evidence and Recommendation Levels of Pregnancy Information in Prescription Drug Labeling in the United States, United Kingdom, Japan, and Korea

2018 ◽  
Vol 27 (9) ◽  
pp. 1086-1092 ◽  
Author(s):  
Yunha Noh ◽  
Dongwon Yoon ◽  
Inmyung Song ◽  
Han Eol Jeong ◽  
Ji Hwan Bae ◽  
...  
Keyword(s):  
United States ◽  
United Kingdom ◽  
Prescription Drug ◽  
The United States ◽  
Drug Labeling

Whatever Happened to the Decade of Pain Control and Research?

2018 ◽  
Author(s):  
John J. Coleman
Keyword(s):  
United States ◽  
Chronic Pain ◽  
Drug Abuse ◽  
Prescription Drug ◽  
Pain Control ◽  
The United States ◽  
Prescription Drug Abuse ◽  
Policy Changes ◽  
Felony Conviction ◽  
Drug Diversion

This chapter discusses how the pharmaceutical industry’s actions affected the accomplishments of the Decade of Pain Control and Research, which began on January 1, 2001, following almost two decades of rising concern over the inadequate treatment of chronic pain in the United States. To tell the story of this decade we must describe the accompanying problem of drug diversion and abuse. The development in 1995 of a new opioid product called OxyContin, its aggressive marketing, the morbidity and mortality associated with its misuse, and the eventual felony conviction in 2007 of the drug’s sponsor for fraudulent claims and marketing practices, affected the Decade in unexpected ways. The response by Congress and the regulatory community to what they termed an “epidemic” of prescription drug abuse produced long-lasting policy changes. The chapter also touches on the peculiar and sometimes troubling relationship between the regulators and the regulated.

scholarly journals PHP32 - IMPACT OF MANUFACTURER COMPETITION ON PRESCRIPTION DRUG PRICE INFLATION IN THE UNITED STATES

2018 ◽  
Vol 21 ◽  
pp. S156
Author(s):  
I. Hernandez ◽  
C.B. Good ◽  
W.F. Gellad ◽  
N. Parekh ◽  
M. He ◽  
...  
Keyword(s):  
United States ◽  
Prescription Drug ◽  
Drug Price ◽  
The United States ◽  
Price Inflation

scholarly journals 377 The prescription drug epidemic in the United States – efforts to improve prescribing

2016 ◽  
Vol 22 (Suppl 2) ◽  
pp. A138.2-A138
Author(s):  
Grant Baldwin ◽  
Debra Houry ◽  
Rita Noonan
Keyword(s):  
United States ◽  
Prescription Drug ◽  
The United States

scholarly journals Illicit and Prescription Drug Misuse among Sexual Minority Women in the United States: A Protocol for a Scoping Review

2020 ◽  
Vol 3 ◽  
pp. 1-12
Author(s):  
Kelly Gagnon ◽  
Jessica Frankeberger ◽  
Stephanie Corey ◽  
Barbara L. Folb ◽  
Christina Mair ◽  
...  
Keyword(s):  
United States ◽  
Substance Use ◽  
Drug Use ◽  
Prescription Drug ◽  
Sexual Minority ◽  
The United States ◽  
Minority Women ◽  
Drug Misuse ◽  
Sexual Minority Women ◽  
Prescription Drug Misuse

  Background: The United States Institute of Medicine (IOM) published reports in 1999 and 2011 identifying drug use as a priority area for sexual minority health research, specifically focused on mechanisms contributing to drug use disparities and the development of tailored interventions. Limited research has prioritized sexual minority women (SMW) with the majority of substance use research among sexual minorities focused on adolescents and men who have sex with men. This scoping review will characterize the research literature related to illicit drug use and prescription drug misuse among SMW and sub-groups within the SMW population. Through this, we will identify: (1) specific substances used; (2) patterns of substance use; (3) risk and protective factors; (4) prevention interventions; and (5) drug treatment programs specific to SMW. Methods/Design: This review will include studies with empirical data of illicit or prescription drug misuse among sexual minority women. Peer-reviewed quantitative research conducted in the United States and published in English from 2011-Present will be included. We will search Medline, PsycINFO, and Web of Science databases for relevant articles. Two independent reviewers will screen abstracts and relevant full-text studies for eligibility. Data will be extracted from eligible articles and results will be presented in narrative and tabular form as appropriate. Discussion: This work will identify gaps of knowledge in the research pertaining to illicit or prescription drug misuse among sexual minority women since the 2011 US IOM report. As a result of this work, we will propose directions for future research to address identified gaps.

Sign in / Sign up

Export Citation Format

Share Document